Rheumatology in West Orange, NJ
3 verified rheumatology doctors in West Orange.
Rheumatologists treat autoimmune and inflammatory conditions affecting the joints, muscles, and connective tissue.
NPPES tenure ≠ clinical experience. "Years on NPPES" is time since the physician first registered a National Provider Identifier, not time practicing medicine. Verify current license status with the state medical board.
Verify a license at the New Jersey State Board of Medical Examiners
Dr. Andrew Weinberger, MD
Rheumatology
CMS Open Payments· $162.28 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$162.28
Total received
4
Transactions
2
Paying companies
Top paying companies
Among the 6,451 rheumatology doctors we've analyzed, about 56% received any industry payment (median $958 among those who did). This doctor's total ranks around the 57th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US rheumatology doctors.
Payments to Andrew Weinberger do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Nicholas Cannarozzi, MD
Rheumatology
CMS Open Payments· $830.77 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$830.77
Total received
59
Transactions
13
Paying companies
Top paying companies
Among the 6,451 rheumatology doctors we've analyzed, about 56% received any industry payment (median $958 among those who did). This doctor's total ranks around the 71th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US rheumatology doctors.
Payments to Nicholas Cannarozzi do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Larysa Zaputowycz, MD
Rheumatology
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.